• Product Development
  • Clinical Trials
  • Quality
  • GxP Audits
  • Regulatory Affairs
  • Pharmacovigilance
  • QP Service / Importer
RFI

MENU

    RFI

    Drop in a message and we will reach out to you

    RAPS: UK on Brexit Implications: “œSignificant Benefits” to Remain Part of EMA

    The UK government’s EU External Affairs Subcommittee on Tuesday published a report on the implications of Brexit on trade, noting that there may be “significant benefits” in continuing UK participation in the European Medicines Agency (EMA).

    http://www.raps.org/Regulatory-Focus/News/2017/03/14/27109/UK-on-Brexit-Implications-%E2%80%98Significant-Benefits%E2%80%99-to-Remain-Part-of-EMA/

    RETURN